After years of preparation, Eli Lilly is on the brink of launching ... head of connected care for Lilly Diabetes. "Using the learnings from early adopters of Tempo, we look forward to continually ...

Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced a successful Phase 3 trial for a once-daily GLP-1 pill for ...

Eli Lilly said its experimental pill met its goals in a pivotal study, helping diabetes patients lower blood sugar—and even reduce weight, bringing an oral version of the booming class of drugs ...

Injectables for type 2 diabetes and weight loss could soon be a thing of the past. Eli Lilly announced Thursday the successful completion of a phase 3 trial of Orforglipron – the first small ...

Eli Lilly's shares were rallying ahead of the opening bell after the drug company's first GLP-1 pill for diabetes and weight loss took a step closer to hitting the market. In premarket trading ...

Eli Lilly experienced a 16% price increase last ... trial for Orforglipron highlight potential new treatments for type 2 diabetes. These innovative steps likely bolstered investor confidence ...

April 17 (UPI) --People diagnosed with type 2 diabetes might benefit soon from Eli Lilly's new orforglipron weight loss drug following its latest clinical testing, the Indianapolis-based drugmaker ...

Some of the potential iterations of delivery methods Eli Lilly considered for orforglipron ... But this one, for Lilly’s first diabetes and weight-loss pill based on the GLP-1 hormone, was ...